Recent Episodes
Understanding Waldenström Macroglobulinemia
Shayna Sarosiek, MD, Dana Farber Cancer Institute, Boston, MA
CAR T-cell Therapy in Review 2022: Updates in Treatment
Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX
Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia: Part II
Daphne Friedman, MD, Durham VA Health Care System, Durham, NC
AML: Insights, Updates, and Takeaways
Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Insights from Attending the 2022 Society of Hematologic Oncology (SOHO) Annual Meeting
Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY
What’s New in the Treatment of BPDCN?
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Categories
- All Episodes (89)
- CAR T-cell Therapy (10)
- Clinical Trials (4)
- COVID-19 (7)
- General Treatment & Support (28)
- Genomics (3)
- Health Equity (7)
- Leukemia (21)
- Lymphoma (11)
- Minimal Residual Disease (MRD) (3)
- Myelodysplastic Syndromes (5)
- Myeloma & Amyloidosis (11)
- Myeloproliferative Neoplasms (3)
- Pediatric and AYA (12)
- Rare Blood Cancers (4)
- Transplantation (4)
- Waldenström macroglobulinemia (2)
